Knownwell Review
Best for: Patients wanting branded GLP-1s with obesity-medicine oversight and insurance options
Knownwell is a weight-inclusive metabolic and primary care company co-founded by obesity-medicine specialist Dr. Angela Fitch. It offers branded GLP-1 medications including Wegovy, Zepbound, Ozempic and Saxenda, plus the oral GLP-1 Foundayo, via virtual visits in all 50 states and in-person clinics in Boston, Chicago, Dallas-Fort Worth and Atlanta. Knownwell is a LillyDirect care provider and a Novo Nordisk telehealth partner for the Wegovy pill. Care combines physician oversight with dietitians and coaches. Many insurance plans are accepted, with copays as low as $25 for covered patients.
Medium confidence · Last verified 2026-06-04 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Knownwell is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Knownwell prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Zepbound self-pay (via LillyDirect) | brand | $349 |
✓ Pros
- •Co-founded by obesity-medicine specialist Dr. Angela Fitch
- •Branded FDA-approved GLP-1s (Wegovy, Zepbound, Ozempic, Saxenda)
- •Official LillyDirect provider and Novo Wegovy-pill telehealth partner
- •Accepts insurance, copays as low as $25 for covered patients
- •Weight-inclusive care with dietitians and health coaches
- •Both virtual (50 states) and in-person clinic options
✗ Cons
- •Specific self-pay monthly medication prices not transparently posted
- •In-person clinics limited to four metro areas
- •Branded-only focus can mean higher cost than compounded routes
Ready to start with Knownwell?
Starting at $349/month. See current pricing and start your free consultation.
Sources & methodology
Our Knownwell review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of June 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 7.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Knownwell
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-brand compounded GLP-1 with hormone and performance programs
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Knownwell?
Starting at $349/month. See current pricing and start your free consultation.